Remifentanil in paediatric anaesthetic practice

Department of Anaesthesia, Queen Alexandra Hospital, Portsmouth, UK.
Anaesthesia (Impact Factor: 3.38). 04/2009; 64(3):301-8. DOI: 10.1111/j.1365-2044.2008.05731.x
Source: PubMed


Remifentanil is a synthetic opioid, first introduced into clinical practice in 1996. Its unique pharmacokinetic profile has resulted in a gradual increase in its popularity in paediatric anaesthesia. It is an opioid of high potency and rapid clearance, consequently lacking problems of accumulation. These characteristics give it a high degree of predictability and it has become an attractive choice for a wide variety of anaesthetic challenges, from premature neonates to the elderly. Neonates and infants have a higher clearance than older children and, as a result, remifentanil has additional benefits in this group. Remifentanil can be described as the only consistently predictable opioid in paediatric practice.

11 Reads
  • Source
    • "Its use is increasing in anaesthetic practice due to its reported haemodynamic and respiratory profile, although a recent review concluded that high-level evidence was lacking. It has further been suggested that it may have a significant volatile sparing effect and obtund the stress response (Marsh and Hodkinson, 2009). Ketamine is gaining popularity as it produces 'dissociative analgesia', allowing a patient to be virtually awake yet pain free. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Trauma forms the second largest cause of death in children under 1 year of age. Infants form a difficult cohort of patients; their range of development, differing physiology and inability to communicate or understand treatment makes them a challenge for any healthcare worker. Several factors compound this problem including a general lack of familiarity within non-specialised trauma services and the difficulty in studying infants as a cohort in academic research. This article aims to summarise the common problems encountered in dealing with infants in a trauma setting and specific differences in their management compared to other children or adults. Where possible it details current evidence most appropriate to the age group.
    Trauma 10/2010; 12(4):211-219. DOI:10.1177/1460408610378269
  • Source
    • "The half life is 4 minutes, and unlike other synthetic opioids which are metabolized by hepatic elimination, remifentanil is metabolized by nonspecific tissue and plasma esterases, thereby eliminating accumulation. Remifentanil is also commonly used in combination with other sedatives such as propofol or midazolam for short painful procedures [16]. Significant dose-dependent bradycardia can be associated with remifentanil administration. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sedation and analgesia performed by the pediatrician and pediatric subspecialists are becoming increasingly common for diagnostic and therapeutic purposes in children with developmental disabilities and neurologic disorders (autism, epilepsy, stroke, obstructive hydrocephalus, traumatic brain injury, intracranial hemorrhage, and hypoxic-ischemic encephalopathy). The overall objectives of this paper are (1) to provide an overview on recent studies that highlight the increased risk for respiratory complications following sedation and analgesia in children with developmental disabilities and neurologic disorders, (2) to provide a better understanding of sedatives and analgesic medications which are commonly used in children with developmental disabilities and neurologic disorders on the central nervous system.
    International Journal of Pediatrics 07/2010; 2010. DOI:10.1155/2010/189142
  • Source
Show more


11 Reads